Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Royalty Pharma plc (RPRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "ROYALTY PHARMA REPORTS SECOND QUARTER 2023 RESULTS"
05/09/2023 8-K Quarterly results
Docs: "ROYALTY PHARMA REPORTS FIRST QUARTER 2023 RESULTS"
03/28/2023 8-K Quarterly results
03/15/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ROYALTY PHARMA RAISES FULL YEAR 2023 GUIDANCE • Royalty Pharma now expects 2023 Adjusted Cash Receipts to be between $2,850 million and $2,950 million, excluding contributions from future transactions."
01/09/2023 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
Docs: "ROYALTY PHARMA REPORTS THIRD QUARTER 2022 RESULTS"
10/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "ROYALTY PHARMA REPORTS SECOND QUARTER 2022 RESULTS"
07/13/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/15/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Opinion of Davis Polk & Wardwell London LLP with respect to the Securities"
04/04/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from EY Ireland",
"Letter from EY Ireland"
02/15/2022 8-K Quarterly results
Docs: "ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2021 RESULTS"
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ROYALTY PHARMA HIGHLIGHTS ACCOMPLISHMENTS AND PROVIDES BUSINESS UPDATE AT 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE • 2021 Net cash provided by operating activities expected to be in the range of $2,010 to $2,030 million; 2021 Adjusted Cash Receipts expected to be at high end of guidance range of $2,110 to $2,130 million • 20 therapies added to portfolio in 2020-2021; 9 are currently or projected to be blockbusters • Announced transactions of $5.5 billion from 2020-2021 expected to add >$750 million to Adjusted Cash Receipts in 2025 , January 10, 2022 - Royalty Pharma plc today provided an update on its business performance, including recent key accomplishments and the full-year 2021 outlook for Net cash provided by operating activities and Adjusted Cash Receipts . Pablo Legorreta, Roy..."
11/10/2021 8-K Quarterly results
Docs: "PRESS RELEASE ROYALTY PHARMA REPORTS THIRD QUARTER 2021 RESULTS"
08/11/2021 8-K Quarterly results
07/26/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Second Supplemental Indenture, Royalty Pharma plc, Royalty Pharma Holdings Ltd. and Wilmington Trust, National Association, as Trustee",
"Opinion of Davis Polk & Wardwell LLP with respect to the Securities",
"Opinion of Davis Polk & Wardwell London LLP with respect to certain matters of English law"
07/16/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among Royalty Pharma plc, Royalty Pharma Holdings Limited, RP Management, LLC and the underwriters named therein"
06/25/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "FORM 8-K"
06/02/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"ROYALTY PHARMA REPORTS THIRD QUARTER 2020 RESULTS"
11/05/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 2 to the Amended and Restated Purchase and Sale Agreement, by and among RPI Finance Trust, RPI 2019 Intermediate Finance Trust and Cystic Fibrosis Foundation"
09/02/2020 8-K Quarterly results
08/19/2020 8-K Quarterly results
08/12/2020 8-K Quarterly results
08/03/2020 8-K/A Quarterly results
08/03/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy